Healthcare & Insurance
Zealand Pharma completes the acquisition of Valeritas
Company announcement – No. 15 / 2020 Zealand Pharma completes the acquisition of Valeritas Zealand Pharma (NASDAQ: ZEAL) has acquired Valeritas Holdings, Inc. (NASDAQ: VLRX), a U.S. based commercial-stage company for a cash purchase price of $23 million The marketed V-Go® wearable insulin
Thursday, April 02, 2020
RETRANSMISSION - PREMIER HEALTH OF AMERICA INC. COVID-19 BUSINESS UPDATE
MONTREAL, April 02, 2020 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (formerly known as Physinorth Acquisition Corporation Inc.) (TSXV: PHA)) (the “Corporation”) wishes to provide a business update in relation with the recent evolution of the Covid-19 situation. Current situation
Thursday, April 02, 2020
RETRANSMISSION - PREMIER HEALTHCARE OF AMERICA ANNOUNCES THAT ITS SUBSIDIARY EXCEL SANTÉ INC. WAS SELECTED BY THE PROVINCIAL GOVERNMENT
MONTREAL, April 02, 2020 (GLOBE NEWSWIRE) -- Premier Healthcare of America (the "Company" or "PHA") is pleased to announce that its subsidiary Excel Santé Inc. ("Excel") has been selected by the Quebec Côte-Nord CISSS ("CISSS") for the issuance of a standing offer for temporary nursing
Thursday, April 02, 2020
La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19
SAN DIEGO, April 02, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it is providing
Thursday, April 02, 2020
Fluidigm CyTOF Technology Used to Evaluate Stem Cell Therapy as a Potential Treatment for COVID-19 Pneumonia
SOUTH SAN FRANCISCO, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Fluidigm® CyTOF® technology was used in a clinical study
Thursday, April 02, 2020
Aesthetic Medical International Holdings Group Limited Enters into Definitive Agreements to Acquire Controlling Interest in Two Treatment Centers
Shenzhen, April 02, 2020 (GLOBE NEWSWIRE) -- Aesthetic Medical International Holdings Group Limited (the “Company” or Nasdaq: AIH), a leading provider of aesthetic medical services in China, today announced the Company, through its affiliates, entered into definitive agreements (the
Thursday, April 02, 2020
Algernon Provides Update on Phase 2 Human Testing of Ifenprodil for COVID-19
VANCOUVER, British Columbia, April 02, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that the protocol for a planned physician
Thursday, April 02, 2020
InsuraGuest Technologies Spotlighted in Broadcast Discussing Insurtech’s Indelible Impact on Insurance Sector
NEW YORK, April 02, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – InsuraGuest Technologies Inc. (TSX.V: ISGI) announces the availability of a broadcast titled, “Technology Transforms the Insurance Market.” To hear the AudioPressRelease from NetworkNewsAudio, visit: http://nnw.fm/5GVQu
Thursday, April 02, 2020
Galectin Therapeutics Update on the Impact of COVID-19
NORCROSS, Ga., April 02, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins today provided an update on the impact of the COVID-19 pandemic on the Company and its clinical trial activities. As the global
Thursday, April 02, 2020
Crown Bioscience Expands PDX Collection with Acquisition of Unique Models from Leading Academic Medical Centers
Agreements with CoMotion at the University of Washington and Dana-Farber Cancer Institute add new prostate cancer and lymphoma models to the world’s largest PDX collectionSAN DIEGO, April 02, 2020 (GLOBE NEWSWIRE) -- Crown Bioscience today announced the strategic expansion of their PDX
Thursday, April 02, 2020
Nova Leap Health Corp. Announces Organic Expansion to the State of Ohio
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, April 02, 2020 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a 2019 TSX Venture 50™ ranked company focused on the home health care
Thursday, April 02, 2020
VigiLanz® Announces Precision Dosing Powered by Tabula Rasa HealthCare’s DoseMeRx™
DoseMeRx to integrate with VigiLanz clinical surveillance solutions for hospitalsMOORESTOWN, N.J., April 02, 2020 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc® (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, has partnered with VigiLanz®, the
Thursday, April 02, 2020
Spectral Provides Update on the Commercial Development of its SAMI Device for Continuous Renal Replacement Therapy
Two new hospitals in Canada and the U.S. place orders for SAMITORONTO, April 02, 2020 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, is pleased to provide an
Thursday, April 02, 2020
Galera Therapeutics Appoints Linda B. West to Board of Directors
MALVERN, Pa., April 02, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today
Thursday, April 02, 2020
ALIGN TECHNOLOGY COMPLETES ACQUISITION OF EXOCAD, A GLOBAL DENTAL CAD/CAM SOFTWARE LEADER
SAN JOSE, Calif. and DARMSTADT, Germany, April 02, 2020 (GLOBE NEWSWIRE) -- Align Technology, Inc. (Align) (Nasdaq: ALGN) today announced that it has completed the acquisition of privately-held exocad Global Holdings GmbH (exocad), a global leader in the dental CAD/CAM software market that offers
Thursday, April 02, 2020
Menlo Announces Settlement to Conclude Finacea Foam Litigation and Announces that Partner, LEO Pharma A/S, Remedies Finacea Foam Supply Issues
BRIDGEWATER, N.J., April 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that its
Thursday, April 02, 2020
Eve & Co Commences Canadian Medical Sales through Cannalogue
STRATHROY, Ontario, April 02, 2020 (GLOBE NEWSWIRE) -- Eve & Co Incorporated (“Eve & Co” or the “Company”) (TSX-V: EVE; QTCQX: EEVVF) is pleased to announce that it has, through its wholly-owned subsidiary Natural MedCo Ltd., entered the Canadian medical cannabis market through
Thursday, April 02, 2020
Spring Bank Provides Update on Business Operations & Clinical Program Progress During COVID-19 Pandemic
Pursuing collaborations to develop internal compounds for potential treatment of COVID-19Safety Review Committee for IV SB 11285 Phase 1a/1b trial recommends dose escalation to next planned dose level; initial patient dosed in next cohortClinical abstracts for IV SB 11285 Phase 1a/1b trial accepted
Thursday, April 02, 2020
Intra-Cellular Therapies Initiates Promotional Activities for CAPLYTA™ (lumateperone) for the Treatment of Schizophrenia in Adults
Intra-Cellular Therapies launches LYTAlink™, a comprehensive patient affordability and access program for CAPLYTANEW YORK, April 02, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of
Thursday, April 02, 2020
Tetra Bio-Pharma Maps Out Cannabinoid Metabolites in Humans Following Inhalation of QIXLEEF
Bioanalytical methods developed and validated for its clinical trials. Tetra initiates study to quantify phytocannabinoid metabolites and precursors and minor phytocannabinoids in human plasma. OTTAWA, April 02, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”)
Thursday, April 02, 2020
